NASDAQ:SNTI Senti Biosciences (SNTI) Stock Price, News & Analysis $2.33 +0.08 (+3.56%) (As of 11/14/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About Senti Biosciences Stock (NASDAQ:SNTI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Senti Biosciences alerts:Sign Up Key Stats Today's Range$2.20▼$2.3350-Day Range$2.04▼$3.1552-Week Range$1.52▼$7.43Volume3,011 shsAverage Volume227,044 shsMarket Capitalization$10.67 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewSenti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Read More… The next assassination attempt won’t be on Trump (Ad)President Trump is soon to be back in the White House. Unity has been restored to the U.S. But if you watched the President’s 25-minute victory speech, you probably noticed he spent nearly four minutes speaking about one very controversial person.I share with you in this special investigative documentary. Senti Biosciences Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks19th Percentile Overall ScoreSNTI MarketRank™: Senti Biosciences scored higher than 19% of companies evaluated by MarketBeat, and ranked 906th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Senti Biosciences. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Senti Biosciences is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Senti Biosciences is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSenti Biosciences has a P/B Ratio of 0.16. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.27% of the float of Senti Biosciences has been sold short.Short Interest Ratio / Days to CoverSenti Biosciences has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Senti Biosciences has recently increased by 9.97%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSenti Biosciences does not currently pay a dividend.Dividend GrowthSenti Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.27% of the float of Senti Biosciences has been sold short.Short Interest Ratio / Days to CoverSenti Biosciences has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Senti Biosciences has recently increased by 9.97%, indicating that investor sentiment is decreasing significantly. News and Social Media3.3 / 5News SentimentN/A News SentimentSenti Biosciences has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Senti Biosciences this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for SNTI on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Senti Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Senti Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders15.90% of the stock of Senti Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 25.73% of the stock of Senti Biosciences is held by institutions.Read more about Senti Biosciences' insider trading history. Receive SNTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Senti Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address SNTI Stock News HeadlinesSenti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate HighlightsNovember 14 at 4:05 PM | globenewswire.comReviewing Recursion Pharmaceuticals (NASDAQ:RXRX) and Senti Biosciences (NASDAQ:SNTI)November 4, 2024 | americanbankingnews.comThe next assassination attempt won’t be on TrumpPresident Trump is soon to be back in the White House. Unity has been restored to the U.S. But if you watched the President’s 25-minute victory speech, you probably noticed he spent nearly four minutes speaking about one very controversial person.November 14, 2024 | Porter & Company (Ad)Senti Biosciences (NASDAQ:SNTI) Stock Quotes, Forecast and News SummarySeptember 26, 2024 | benzinga.comSenti Bio to Participate in Upcoming Investor ConferencesSeptember 3, 2024 | globenewswire.comSenti Biosciences, Inc.: Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline HighlightsAugust 14, 2024 | finanznachrichten.deSNTI Stock Earnings: Senti Biosciences Reported Results for Q2 2024August 14, 2024 | investorplace.comSenti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline HighlightsAugust 13, 2024 | globenewswire.comSee More Headlines SNTI Stock Analysis - Frequently Asked Questions How have SNTI shares performed this year? Senti Biosciences' stock was trading at $6.60 at the beginning of the year. Since then, SNTI stock has decreased by 64.7% and is now trading at $2.33. View the best growth stocks for 2024 here. When did Senti Biosciences' stock split? Shares of Senti Biosciences reverse split on the morning of Thursday, July 18th 2024. The 1-10 reverse split was announced on Thursday, July 18th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 18th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are Senti Biosciences' major shareholders? Senti Biosciences' top institutional investors include 8VC GP I LLC (5.54%) and ARK Investment Management LLC (3.86%). View institutional ownership trends. How do I buy shares of Senti Biosciences? Shares of SNTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Senti Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Senti Biosciences investors own include NVIDIA (NVDA), PayPal (PYPL), Meta Platforms (META), Pfizer (PFE), Advanced Micro Devices (AMD), Coinbase Global (COIN) and SoFi Technologies (SOFI). Company Calendar Today11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SNTI CUSIPN/A CIK1854270 Webwww.sentibio.com Phone650-239-2030FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($12.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-71,060,000.00 Net MarginsN/A Pretax Margin-23,259.76% Return on Equity-84.70% Return on Assets-48.10% Debt Debt-to-Equity RatioN/A Current Ratio4.89 Quick Ratio4.89 Sales & Book Value Annual Sales$2.56 million Price / Sales4.20 Cash FlowN/A Price / Cash FlowN/A Book Value$15.02 per share Price / Book0.16Miscellaneous Outstanding Shares4,580,000Free Float3,851,000Market Cap$10.76 million OptionableNot Optionable Beta2.74 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:SNTI) was last updated on 11/14/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThis small cap’s electric marine powertrain broke the world speed recordThe future of marine propulsion has arrived-powered by a $2 billion powerhouse. In collaboration with McLar...The Tomorrow Investor | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredTrump’s Back, but DC’s Coming for Your Money!Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Senti Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Senti Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.